Skip to main content
Equibles
BNTC logo

BNTC · Benitec Biopharma Inc.

Track BNTC — free

Use BNTC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BNTC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$12.51 -0.17 (-1.30%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$438.36M
Shares
34.35M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-05-14 Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Event
2026-04-28 Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting Shareholder meeting
2026-03-10 Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) Conference
2026-03-09 Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference Conference
2026-02-23 Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference Conference
2026-02-12 Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update Event
2026-01-11 Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Event
2025-11-14 Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update Event
2025-11-06 Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering Event
2025-11-05 Benitec Biopharma Inc. Announces Proposed Public Offering Event

Source: https://ir.benitec.com/

Key facts CIK 1808898 CUSIP 08205P209 13F (30d) 76 filings 76 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)